Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease Borja Quiroga, Patricia Muñoz Ramos, Vicente Álvarez Chiva

Cardiovascular risk prediction in chronic kidney disease patients Santiago Cedeño Mora, Marian Goicoechea, Esther Torres, Úrsula Verdalles, Ana Pérez de José, Eduardo Verde, Soledad García de Vinuesa, José Luño

Experience with PCSK9 inhibitors from a Nephrology unit Verónica Escudero Quesada, Jonay Pantoja Pérez, Cristina Castro Alonso, July Vanessa Osma Capera, Alejandro Valero Antón, Asunción Sancho Calabuig